Clinical Trial Update: Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of erlotinib and pemetrexed for lung adenocarcinoma with brain metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Lung Adenocarcinoma

Drugs mentioned

• Alimta (pemetrexed)
• Tarceva (erlotinib)

Snippet

Sponsor: Guangzhou Medical University | Conditions: Lung Adenocarcinoma, Brain Metastases | Phase 2 | Status: COMPLETED